Related Experiment Videos
Drug Wins Designation as a Biosimilar Product to Humira
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
The American Journal of Nursing
|January 27, 2022
Abstract:
Adalimumab-adbm (Cyltezo) has been approved as an interchangeable biosimilar product to adalimumab (Humira). This means it can be substituted at the pharmacy for Humira without being specified in the prescription.Nurses should inform patients who have been receiving Humira that they may receive Cyltezo instead, and that this is not a pharmacy error.